Investigates how self-assembled nanoparticles reduce ulcerative colitis symptoms, highlighting a new treatment approach.
Key Points
To evaluate the therapeutic effects of self-assembled nanoparticles from Xiexin Decoction on ulcerative colitis and understand their mechanism of action.
Investigated self-assembled nanoparticles (XDNPs) and carrier-free nanoparticles (RBNPs) from Xiexin Decoction
Assessed the impact on DSS-induced colitis in vivo
Conducted proteomic and molecular analyses to explore immune modulation
Evaluated biocompatibility and organ toxicity through in vivo assessments.
XDNPs and RBNPs effectively reduced symptoms of DSS-induced colitis
Normalizing gut dysbiosis and decreasing pro-inflammatory mediator release
Identified VDAC1 as a target for berberine, preventing NLRP3 inflammasome activation
Demonstrated excellent biocompatibility without organ toxicity.